Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Operations (Unaudited)

v3.22.0.1
Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Expenses        
Research and development $ 3,902 $ 2,584 $ 7,695 $ 3,941
General and administrative 1,993 2,794 4,171 4,329
Merger costs       500
In-process research and development     16,094 16,094
Operating Expenses (5,895) (5,378) (11,866) (24,864)
Other income (loss)        
Foreign exchange 1 (3) 5 (2)
Amortization of deferred loan costs   (25)   (51)
Interest, net 1 (7) 2 (14)
Other loss (income) 2 (35) 7 (67)
Net loss for the period (5,893) (5,413) (11,859) (24,931)
Computation of basic loss per share        
Net loss for the period (5,893) (5,413) (11,859) (24,931)
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance       (3,181)
Series A Preferred cash dividend (2) (2) (4) (4)
Series B Preferred stock dividend   (4)   (9)
Series C Preferred stock dividend     (2,462)  
Net loss for the period attributable to common stockholders $ (5,895) $ (5,419) $ (14,325) $ (28,125)
Basic and fully diluted loss per share $ 0.12 $ 0.22 $ 0.35 $ (1.34)
Basic and fully diluted weighted average number of shares 48,529,000 24,845,000 41,405,000 20,976,000